Related Experiment Video
Updated: Sep 28, 2026

Artificial Antigen Presenting Cell (aAPC) Mediated Activation and Expansion of Natural Killer T Cells
Published on: December 29, 2012
Detection and activation of human Valpha24+ natural killer T cells using alpha-galactosyl ceramide-pulsed dendritic
Shin-ichiro Fujii1, Kanako Shimizu, Ralph M Steinman
1Laboratory of Tumor Immunology and Immunotherapy, The Rockefeller University, New York, NY 10021, USA.
Insights
A new enzyme-linked immunospot (ELISPOT) assay quantifies human natural killer T (NKT) cells in blood. Mature dendritic cells (DCs) pulsed with alpha-galactosylceramide (alpha-GalCer) are optimal for NKT cell activation and expansion.
Area of Science:
- Immunology
- Cellular immunology
- Immunotherapy
Background:
- Natural killer T (NKT) cells regulate immune responses and can be activated by alpha-galactosylceramide (alpha-GalCer) presented by CD1d molecules on antigen-presenting cells (APCs).
- Quantifying NKT cell function in fresh human blood is crucial for research and therapeutic applications.
Purpose of the Study:
- To develop a simple method for quantifying human NKT cell function in fresh blood.
- To investigate the requirements for NKT cell activation by alpha-GalCer-loaded APCs.
- To optimize conditions for NKT cell expansion and generation of NKT cell lines.
Main Methods:
- Development and application of an enzyme-linked immunospot (ELISPOT) assay for quantifying freshly isolated human NKT cells.
- Evaluation of different APC types (monocytes, macrophages, dendritic cells) for NKT cell activation.
- Assessment of NKT cell function (cytokine secretion, target killing) after expansion with dendritic cells (DCs).
Main Results:
- Freshly isolated human NKT cells can be quantified using an ELISPOT assay after stimulation with alpha-GalCer-loaded APCs.
- Monocyte-derived DCs, particularly mature, alpha-GalCer-pulsed DCs, are more effective than monocytes/macrophages for NKT cell activation in fresh blood.
- NKT cells expanded with DCs exhibit enhanced functionality, secreting both IFN-gamma and IL-4, and demonstrate cytotoxic activity.
Conclusions:
- The ELISPOT assay provides a simple and effective method for monitoring human NKT cell function.
- Mature, alpha-GalCer-pulsed DCs are optimal for NKT cell activation and expansion, offering a promising strategy for immune therapeutic targeting.
- These findings establish conditions for DC loading with alpha-GalCer and provide a tool for NKT cell monitoring in clinical settings.
Abstract:
Human CD1d-restricted natural killer T (NKT) cells, which are postulated to regulate the immune response in several clinical settings, can be activated by alpha-galactosylceramide (alpha-GalCer) presented by CD1d molecules on antigen presenting cells (APCs). Simple methods to quantify NKT function in fresh blood will greatly benefit studies targeting NKT cells in humans. Here we show that freshly isolated human NKT cells can be readily quantified by an enzyme-linked immunospot (ELISPOT) assay and have a Th1 profile (secreting interferon-gamma, but not IL-4), after stimulation using alpha-GalCer loaded APCs. Using this assay, we also evaluated APC requirements for human NKT cell activation in fresh blood. Monocyte-derived dendritic cells (DCs) are more effective than monocytes/macrophages for detecting and activating NKT cells in fresh blood, with mature alpha-GalCer pulsed DCs being optimal. DCs are also efficient APCs for expanding NKT cells in culture and generating NKT cell lines. NKT cells expanded with DCs were functional, secreting both IFN-gamma and IL-4, and killing NKT-sensitive targets. Optimal activation of these lines was seen using mature DCs loaded with 10-100 ng/ml of alpha-GalCer. DCs matured with several different stimuli were effective. These data help to establish the conditions for loading DCs with alpha-GalCer for immune therapeutic targeting of NKT cells, and provide a new simple assay to monitor NKT function in humans.
More Related Videos
08:52Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
09:54Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
Published on: May 22, 2020